Skip to content
A Green Sign – Lifestyle
Author:
Nuvectis Pharma, Inc.
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
June 22, 2026
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
May 14, 2026
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
May 5, 2026
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
March 31, 2026